CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
Might the CSL Limited (ASX:CSL) share price be an opportunity after the healthcare giant recently released its FY21 result?
The Nanosonics Ltd (ASX: NAN) share price has gone bonkers this morning, up 18% to $6.99 as the market reacts to its latest product release.
A look at Pro Medicus Ltd (ASX:PME), Redbubble Ltd (ASX:RBL), Nearmap Ltd (ASX:NEA), CSL Limited (ASX:CSL), Netwealth Ltd (ASX:NWL), AVA Risk Group Ltd (ASX:AVA) and Upstart Inc (NASDAQ:UPST).
On The Australian Investors Podcast, watch or listen along as analyst Owen Rask and 7Investing’s Dr Anirban Mahanti dive into results from Pro Medicus (ASX: PME), Redbubble Ltd (ASX: RBL), Netwealth (ASX: NWL), CSL Limited (ASX: CSL) and more.
What a week of ASX Reporting Season! The results are in Commonwealth Bank (ASX:CBA), BHP Group Ltd (ASX:BHP), and CSL Limited (ASX:CSL).
The S&P/ASX 200 (ASX: XJO) fell 0.1% on Wednesday solely due to a 7.1% fall in BHP Group Ltd (ASX: BHP) as investors digest the merger.
Australia’s third-largest public company CSL Limited (ASX: CSL) achieved steady growth in FY21 despite intermittent lockdowns.
The S&P/ASX 200 (ASX:XJO) finished at another record high on Friday as positive sentiment from ASX reporting season continued another week.
The S&P/ASX 200 (ASX: XJO) charged 2% higher for the week while all three US benchmarks recorded weekly gains. Here are my key takeaways.
